Aim To conduct a systematic review of observational studies to explore the real‐world
kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse …

Background: Frailty is a multidimensional condition often diagnosed in older adults with
hypertension and diabetes, and both these conditions are associated with endothelial …

Background A precision medicine approach in type 2 diabetes requires the identification of
clinical and biological features that are reproducibly associated with differences in clinical …

Background There have been scarce data comparing cardiovascular outcomes between
individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the …

Data comparing kidney outcomes between individual sodium-glucose cotransporter-2
(SGLT2) inhibitors are limited. Here, we aimed to compare the subsequent risk of …

Matching is a technique through which patients with and without an outcome of interest (in
case-control studies) or patients with and without an exposure of interest (in cohort studies) …

In 2021, 217 excellent manuscripts were published in Hypertension Research. Editorial
teams greatly appreciate the authors' contribution to hypertension research progress. Here …

ABSTRACT Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral
anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors …

The increasing number of patients undergoing dialysis due to diabetes mellitus (DM) is
causing serious economic problems, and its reduction is an urgent policy issue in developed …

Context Diabetic kidney disease is a major burden among diabetic patients. Sodium-
glucose cotransporter 2 inhibitors (SGLT2is) were shown to reduce renal outcomes in …